Company Overview and News


Add PLSE
to your dashboard

Headline News

Pulse Biosciences' (PLSE) CEO Darrin Uecker on Q4 2017 Results - Earnings Call Transcript

2017-11-11 seekingalpha
Good afternoon, ladies and gentlemen, and welcome to the Pulse Biosciences Fourth Quarter Investor Update Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded. (98-1)

Corporate News Blog - Medical Technology Company Pulse Biosciences Announces Changes to its Board

2017-11-06 accesswire
LONDON, UK / ACCESSWIRE / November 6, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Pulse Biosciences, Inc. (NASDAQ: PLSE), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=PLSE. The Company announced on November 03, 2017, changes to its Board of Directors. The changes are due to the retirement of four members which includes former Chairman Robert Levande and independent directors Mitchell Levinson; Robert Greenberg, M. (216-0)

Biotech Forum Daily Digest: Revisiting Radius Health

2017-09-14 seekingalpha
The main biotech indices are down slightly on the week in listless trading as the sector consolidates recent gains. (7-2)

Pulse Biosciences: It's All Relative - The Qualitative Aspect Of Insider Behavior

2017-08-09 seekingalpha
Private investor Robert Duggan's recent buys extend the window to February before he can sell shares. (0-7)

Duggan Robert W buys shares of PLSE / Pulse Biosciences, Inc. - Fintel.io

2017-08-03 fintel.io
August 03, 2017 - Duggan Robert W has filed a SC 13D/A form disclosing ownership of 3,422,694 shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) corresponding to a(n) 23.9 ownership percentage. (0-2)

Pulse Biosciences' (PLSE) CEO Darrin Uecker on Q2 2017 Results - Earnings Call Transcript

2017-07-29 seekingalpha
Good day, ladies and gentlemen, and welcome to the Pulse Biosciences Quarterly Investor and Analyst Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded. (0-1)

The Big Deal About Stem Cell Therapies and Regenerative Medicine

2017-07-28 prnewswire
Stem cell therapies are a key component of the regenerative medicine field that promises to be a revolutionary approach to treating many degenerative conditions by repairing damaged tissue and harnessing the body's ability to heal itself. Biotech companies in focus include: Endonovo Therapeutics, Inc. (OTCQB: ENDV), Pulse Biosciences, Inc. (NASDAQ: PLSE), Pluristem Therapeutics, Inc. (NASDAQ: PSTI), Cytori Therapeutics, Inc. (0-1)

Congress Could Have Major Impact on Biotech Companies

2017-07-21 prnewswire
Senate Republicans introduced a revised version of the health care repeal aiming to replace the Affordable Care Act earlier this month. Repealing the law was a top priority for Mr. Trump and Republicans in Congress, claiming the law has driven up premiums and forced consumers to buy insurance they cannot afford and do not want.

Congress Could Have Major Impact on Biotech Companies

2017-07-21 prnewswire
Senate Republicans introduced a revised version of the health care repeal aiming to replace the Affordable Care Act earlier this month. Repealing the law was a top priority for Mr. Trump and Republicans in Congress, claiming the law has driven up premiums and forced consumers to buy insurance they cannot afford and do not want.

Pulse Biosciences (PLSE): Shock Therapy Doesn’t Cut It -- 5/23/2017

2017-06-20 feedproxy.google
Pulse Biosciences (PLSE) churns out disappointing study results and accelerated losses, yet the stock has shot up over 400% as unwary investors follow a billionaire’s whims.

Pulse Biosciences Announces Treatment Of First Patient In Study To Evaluate The Safety And Efficacy Of Novel Nano-Pulse Stimulation Technology For Seborrheic Keratosis Lesions

2017-06-06 devicespace
BURLINGAME, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq:PLSE), a medical technology company developing a therapeutic tissue treatment platform based on its proprietary Nano-Pulse Stimulation (NPS) technology, today announced treatment of the first patient in the Company’s multi-center study evaluating the safety and efficacy of the NPS technology for the treatment of seborrheic keratosis (SK).

Implied Volatility Surging for EDAP TMS (EDAP) Stock Options

2017-05-16 zacks
Investors in EDAP TMS S.A. (EDAP - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the May 19th, 2017 $3 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.

Pulse Biosciences, Inc.: High-Voltage Hype Set To Short-Circuit

2017-05-09 seekingalpha
Pulse claims its technology can eliminate tumors and trigger immune responses, but clinical evidence demonstrates worst-in-class efficacy.

Pulse Biosciences' (PLSE) CEO Darrin Uecker on Q1 2017 Results - Earnings Call Transcript

2017-05-06 seekingalpha
Good day ladies and gentlemen and welcome to the Pulse Biosciences Second Quarter 2017 Investor Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder this conference call is being recorded.

CUSIP: 74587B101